Onasemnogene abeparvovec (Zolgensma®) is an approved adeno-associated virus 9 (AAV9) vector ubiquitously expressing a human SMN1 cDNA transgene for infants with SMA, however, lack of efficacy and adverse events have been observed in patients following treatment. Here, SMN1 is linked to proximal spinal muscular atrophy.